InvestorsHub Logo
Followers 48
Posts 3935
Boards Moderated 0
Alias Born 01/26/2011

Re: r622102675 post# 144954

Wednesday, 10/16/2013 7:29:49 PM

Wednesday, October 16, 2013 7:29:49 PM

Post# of 346653
So, 2 companies and their breakthrough therapies have a meeting with the FDA on November 5 to address immune checkpoints in treating pediatric cancer. One company has to try and justify the AEs and the other (Merck) hypothetically could walk in with an upstream immune checkpoint that (maybe) also received BTD and just presented on the combination synergistic effects that make the safety profile better.

Who walks away with the entire pediatric oncology market in immunology?

http://www.fda.gov/AdvisoryCommittees/Calendar/ucm370991.htm

r679953049??? posted earlier
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News